Login
Companies $SLN
$19.83 -$0.00 (0.03%) Live
Silence Therapeutics plc logo

Silence Therapeutics plc

silence-therapeutics.com

What Do They Do?

Develops gene-silencing medicines using short interfering RNA for people with rare and common diseases, including blood, cardiovascular and metabolic conditions.

How Do They Make Money?

Pharmaceutical collaborators pay for research and development work and related rights under collaboration agreements. The company receives fixed upfront payments and may receive milestone payments and reimbursement for staff and research costs; collaboration revenue is spread over the contract period as the work is carried out.

revenue
SegmentShareRevenue
Royalty Income
Licensed
0.0%
FY2022: 3.3%
Research Collaboration Income
100%
FY2022: 97%

Who Are Their Customers?

Pharmaceutical companies buy research and development collaborations and rights related to medicines being developed from the company.

Do Revenues Turn Into Profits?

No. It lost $88.6M in FY2025.

Operating income, FY2025
−16293% of revenue
▼ −44% (Loss) vs FY2024 (−$63.3M, −146%)
Net income, FY2025
−15852% of revenue
▼ −96% (Loss) vs FY2024 (−$45.3M, −105%)
Free cash flow, FY2025
−11150% of revenue
▲ +8% (Loss) vs FY2024 (−$67.9M, −157%)

How Are They Changing?

Since the FY2025 annual report
  • Oct 18, 2026 Merck KGaA agreed to acquire Silence Therapeutics The proposed all-cash transaction is subject to shareholder, court and regulatory approvals and is expected to close in the first quarter of 2027.
  • Aug 10, 2026 Divesiran Phase 2 trial met its primary and secondary endpoints Silence said it expects to start a Phase 3 trial for polycythemia vera in the first half of 2027.
Revenue over time
Royalty Income Research Collaboration Income
$50M$25M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support